Pharma-Bio Serv EBITDA per Employee
The EBITDA per Employee of Pharma-Bio Serv (PBSV) as of Nov 3, 2026 is -2,898.46 USD. In the previous year, EBITDA per Employee was -5,852.67 USD — a change of -50.48% (higher).
Get this data via API
Financial Data API
EBITDA per Employee
-2,898.46USD
YoY
-50.48%
Last updated:
The Pharma-Bio Serv EBITDA per Employee history
3 Years
10 Years
25 Years
Max
| YEAR | EBITDA per Employee | YoY |
|---|---|---|
| -2,898.46USD | -50.48% | |
| -5,852.67USD | -215.23% | |
| 5,079.14USD | -4.90% | |
| 5,340.66USD | -130.49% | |
| -17,516.79USD | -273.16% | |
| 10,116.12USD | +31.17% | |
| 7,712.20USD | +55.91% | |
| 4,946.65USD | -176.36% | |
| -6,477.92USD | +1,453.14% | |
| -417.09USD | -105.15% | |
| 8,097.02USD | -37.81% | |
| 13,018.86USD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Pharma-Bio Serv Stock analysis
Frequently Asked Questions about Pharma-Bio Serv stock
EBITDA per Employee of Pharma-Bio Serv is -2,898.46 USD in 2025.
EBITDA per Employee of Pharma-Bio Serv changed from -5,852.67 USD to -2,898.46 USD, representing a -50.48% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of EBITDA per Employee Pharma-Bio Serv since 2006 – with annual values, charts, and detailed analysis.
EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.
EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Pharma-Bio Serv historically and in real time.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Workforce — Pharma-Bio Serv
All Key Metrics — Pharma-Bio Serv
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth